Kiacta eprodisate: Completed Phase III enrollment

Auven completed enrollment of 230 patients in a double-blind, placebo-controlled, international Phase III trial of oral 400 mg Kiacta. Patients will receive 1-3 capsules of Kiacta twice daily and

Read the full 293 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE